Addendum
Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)
Report documents
-
Extract of the addendum
Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)
-
Addendum to the assessment of potential
Amyloid PET in dementia of unclear aetiology (Addendum to Commission E18-03)
Press releases
Amyloid PET could help patients with dementia of unknown cause: a study now aims to clarify this
If PET can better distinguish between Alzheimer's disease and other forms of dementia, this might allow more precise drug administration and longer maintenance of independence.
Project details
- Project no.
- E18-05
- Commission
- Commission awarded on 01.06.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Non-Drug Interventions
- Topic
- Head and nerves
- Note
-
Within the framework of the testing regulation the Federal Joint Committee (G-BA) can commission IQWiG to assess the potential of a new examination or treatment method (i.e. of a medical device). As part of an administrative procedure conducted by the G-BA, the topics and content of the assessments of the potential of medical devices are confidential until the testing directive is passed.